Fatty liver disease induced by maternal obesity is driven by metabolic rewiring of Kupffer cells
June 30, 2025 / maternal obesity / fatty liver disease / Kupffer cell metabolism / metabolic reprogramming / hepatic inflammation
Maternal obesity reprograms fetal Kupffer cells, causing persistent metabolic shifts that promote fatty liver disease in offspring—even without postnatal dietary triggers—by enhancing hepatocyte lipid uptake through altered immune and energy metabolism pathways.
With China approval, Lilly and Innovent’s mazdutide breaks into new class for GLP-1 obesity drugs
June 27, 2025 / mazdutide approval / GLP-1 obesity treatment / China obesity drug / Innovent Eli Lilly / dual receptor agonist
China has approved mazdutide, the first dual GLP-1/glucagon receptor agonist, for chronic weight management. Phase 3 data show significant weight loss and liver fat reduction, positioning it as a promising new option amid growing obesity rates and therapeutic competition.
Rivus Pharmaceuticals Announces Positive Topline Results from Phase 2 M-ACCEL Trial of HU6 Showing Significant Reductions in Liver Fat in Patients with MASH
June 24, 2025 / HU6 / MASH treatment / liver fat reduction / obesity drug trial / visceral fat loss
Rivus Pharmaceuticals’ Phase 2 M-ACCEL trial of HU6 in MASH patients showed significant liver fat reduction and visceral fat loss, with no lean mass loss. The therapy was well tolerated and also improved metabolic markers like blood pressure and A1c.
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
June 25, 2025 / VK2735 / GLP-1 GIP dual agonist / obesity clinical trial / Viking Therapeutics / weight loss therapy
Viking Therapeutics has launched Phase 3 trials for VK2735, a dual GLP-1/GIP agonist, targeting obesity and type 2 diabetes. VK2735 previously showed significant weight loss and favorable safety in Phase 2 studies, supporting its potential as a metabolic treatment.
‘New possibilities for Envlo confirmed beyond blood sugar lowering, expanding its therapeutic area’
June 30, 2024 / Envlo / enavogliflozin / SGLT-2 inhibitor / metabolic disease therapy / insulin resistance
Daewoong’s SGLT-2 inhibitor Envlo (enavogliflozin) demonstrated metabolic benefits beyond glucose control in a Phase 3 trial, including improved insulin resistance and reduced leptin levels—suggesting a potential adipocyte-targeted mechanism independent of weight loss.
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
June 25, 2025 / obesity treatment / metabolic disease therapy / GDNF biologic / Silo Pharma / Hoth Therapeutics
Silo Pharma and Hoth Therapeutics plan to jointly develop a novel obesity and metabolic disease treatment based on GDNF, a VA-licensed biologic shown to regulate metabolism and reduce obesity in preclinical models, targeting conditions like NAFLD and type 2 diabetes.
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
June 27, 2025 / amycretin weight loss / GLP-1 agonist obesity / triple agonist therapy / obesity clinical trial results / metabolic disease treatment
Metabolics Pharma’s ENT-03 demonstrated sustained weight loss, improved glucose control, and liver health in obese mice, outperforming semaglutide. Its unique central action and PTP1B inhibition suggest potential as a durable obesity and metabolic disease treatment.
Experimental drug promotes weight loss by heating fat instead of suppressing appetite
June 24, 2025 / SANA drug / obesity treatment / thermogenesis activation / adipose tissue targeting / metabolic disease therapy
The experimental drug SANA promotes weight loss by activating UCP1-independent thermogenesis in adipose tissue. It prevents and reverses obesity and related metabolic disorders in mice, offering a novel, appetite-independent mechanism that may complement existing obesity therapies like GLP-1 analogs.
Alternative to GLP-1 drugs may treat diabetes, weight loss without muscle loss
June 27, 2025 / muscle-preserving weight loss / type 2 diabetes treatment / GLP-1 alternative / obesity drug trial / skeletal muscle metabolism
A new oral diabetes and obesity drug from Swedish researchers targets skeletal muscle metabolism to promote weight loss without muscle loss. Early human trials show safety and tolerability, offering a potential alternative to GLP-1 drugs like Ozempic.
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management
June 27, 2024 / dual GCG GLP-1 agonist / obesity drug approval China / mazdutide weight loss / metabolic disease treatment / NMPA obesity therapy
China’s NMPA has approved Innovent’s mazdutide, the first dual GCG/GLP-1 receptor agonist, for chronic weight management. Clinical trials show significant weight loss, reduced visceral fat, and liver fat improvement, offering a novel approach to obesity-related metabolic disorders in China.
Study Evaluates Pregnancy and Breast Milk for Clues to Childhood Obesity
June 30, 2025 / childhood obesity prevention / maternal blood sugar / metabolic programming pregnancy / breast milk fatty acids / infant body fat study
The GROWTH study explores how maternal blood sugar during pregnancy affects breast milk composition and infant body fat, aiming to understand metabolic programming’s role in childhood obesity and identify early interventions to prevent long-term metabolic disease.
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
June 25, 2025 / oral GLP-1/glucagon agonist / obesity treatment tablet / OPK-88006 ENDO 2025 / metabolic disorder therapy / Entera Bio OPKO collaboration
OPKO Health and Entera Bio will present new data on OPK-88006, a first-in-class oral dual GLP-1/glucagon agonist tablet for obesity and metabolic disorders, offering a potentially simpler and more tolerable alternative to injectable incretin therapies.
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects “
June 25, 2025 / ENT-03 clinical trial / obesity diabetes treatment / PTP1B inhibitor weight loss / Metabolics Pharma ENT-03 / insulin sensitivity obesity therapy
Metabolics Pharma’s Phase 1a trial of ENT-03 in obese and diabetic subjects showed the drug was safe, well tolerated, and demonstrated promising trends in weight reduction and insulin sensitivity, supporting its novel mechanism targeting central metabolic regulation.
Efruxifermin Shows Long-Term Promise in MASH-Related Cirrhosis Despite Missing Primary Endpoint in Phase IIb Trial
June 26, 2025 / efruxifermin MASH cirrhosis / FGF21 analogue fibrosis / SYMMETRY trial results / long-term liver disease treatment / metabolic liver fibrosis therapy
Efruxifermin missed its primary endpoint at 36 weeks in MASH-related cirrhosis but showed promising fibrosis improvement and metabolic benefits at 96 weeks, supporting continued evaluation in Phase III trials for long-term efficacy and safety.
Pemvidutide shows benefit for MASH in Phase 2b clinical trial
June 30, 2025 / pemvidutide MASH treatment / Phase 2b IMPACT trial / GLP-1 glucagon dual agonist / liver fibrosis reduction / obesity-related liver disease therapy
Pemvidutide met a primary endpoint in a Phase 2b trial, resolving MASH without worsening fibrosis in over 50% of patients, while also promoting weight loss and reducing liver fat. Longer treatment may improve fibrosis outcomes further.
Weight Loss Drug HU6 Shows Promise in MASH With Muscle-Sparing Benefits
June 28, 2025 / HU6 MASH treatment / fat-specific weight loss / muscle-sparing obesity drug / visceral fat reduction / Rivus Pharmaceuticals liver trial
In the Phase 2 M-ACCEL trial, HU6 significantly reduced liver fat in MASH patients while preserving muscle mass. The oral therapy selectively targets visceral fat, showing promise as a safe, fat-specific treatment for cardiometabolic-driven liver disease.
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
June 27, 2025 / ‘pemvidutide MASH trial / GLP-1 glucagon dual agonist / fibrosis treatment failure / Altimmune Phase IIb results / weight loss liver disease
Altimmune’s pemvidutide met its MASH resolution goal but failed to significantly improve fibrosis in a Phase IIb trial. Despite promising weight loss and liver fat reduction, the lack of fibrosis impact led to investor skepticism and a sharp stock decline.
Insulin resistance test may help predict early Alzheimer’s cognitive decline rate
June 28, 2025 / Insulin resistance / TyG index / Cognitive decline / Early Alzheimer’s / Alzheimer’s progression
A new study shows the TyG index, a simple blood test measuring insulin resistance, may predict the rate of cognitive decline in early Alzheimer’s. Higher TyG levels were linked to a fourfold risk of faster disease progression.
High Uric Acid: How does it lead to sudden heart attack and metabolic syndrome, and ways to manage it
June 29, 2025 / Uric acid / Heart attack / Metabolic syndrome / Inflammation / Hyperuricemia
High uric acid levels (hyperuricemia) are linked to oxidative stress and vascular inflammation, increasing the risk of sudden heart attacks and metabolic syndrome—even in individuals without elevated cholesterol, prompting a reassessment of its broader cardiovascular impact.
Qatar researchers uncover critical link between insulin resistance and early-onset colorectal cancer
June 28, 2025 / Insulin resistance / Colorectal cancer / Early-onset cancer / Metabolic syndrome / Gut microbiome
Researchers in Qatar link insulin resistance to early-onset colorectal cancer (EOCRC), proposing metabolic dysfunction, gut microbiome disruption, and early-life exposures as key drivers. The study underscores the need for early intervention and precision public health strategies.